As part of the agreement, Rentschler will invest in the site over the next five years to bolster their manufacturing capabilities.
This investment is expected to make a ‘major contribution’ to creating suitable manufacturing capability for cell and gene therapies, the CGT Catapult said in a statement.
The German company will establish manufacturing capability in advanced therapy medicinal products (ATMPs), including adeno-associated virus (AAV) Vectors for clinical trial supply.
